$2.5T
Total marketcap
$201.89B
Total volume
BTC 50.11%     ETH 15.71%
Dominance

Prothena PRTA Stock

25.09 USD {{ price }} -3.759109% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
1.35B USD
LOW - HIGH [24H]
24.62 - 26.75 USD
VOLUME [24H]
662.05K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.76 USD

Prothena Price Chart

Prothena PRTA Financial and Trading Overview

Prothena stock price 25.09 USD
Previous Close 71.85 USD
Open 71.65 USD
Bid 0 USD x 800
Ask 0 USD x 800
Day's Range 70.52 - 72.66 USD
52 Week Range 22.97 - 79.65 USD
Volume 357.79K USD
Avg. Volume 470.42K USD
Market Cap 3.83B USD
Beta (5Y Monthly) 0.360211
PE Ratio (TTM) N/A
EPS (TTM) -2.76 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 93 USD

PRTA Valuation Measures

Enterprise Value 3.15B USD
Trailing P/E N/A
Forward P/E -17.786764
PEG Ratio (5 yr expected) 29.12
Price/Sales (ttm) 69.70372
Price/Book (mrq) 6.29347
Enterprise Value/Revenue 57.299
Enterprise Value/EBITDA -21.095

Trading Information

Prothena Stock Price History

Beta (5Y Monthly) 0.360211
52-Week Change 204.02%
S&P500 52-Week Change 20.43%
52 Week High 79.65 USD
52 Week Low 22.97 USD
50-Day Moving Average 64.19 USD
200-Day Moving Average 55.14 USD

PRTA Share Statistics

Avg. Volume (3 month) 470.42K USD
Avg. Daily Volume (10-Days) 426.38K USD
Shares Outstanding 52.75M
Float 38.68M
Short Ratio 5.68
% Held by Insiders 4.72%
% Held by Institutions 95.09%
Shares Short 3.32M
Short % of Float 9.25%
Short % of Shares Outstanding 6.29%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -232.19%
Operating Margin (ttm) -273.0069%
Gross Margin -178.68%
EBITDA Margin -271.61%

Management Effectiveness

Return on Assets (ttm) -14.16%
Return on Equity (ttm) -24.37%

Income Statement

Revenue (ttm) 54.92M USD
Revenue Per Share (ttm) 1.13 USD
Quarterly Revenue Growth (yoy) 88.09%
Gross Profit (ttm) -81657000 USD
EBITDA -149175008 USD
Net Income Avi to Common (ttm) -127523000 USD
Diluted EPS (ttm) -2.45
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 686.18M USD
Total Cash Per Share (mrq) 13.01 USD
Total Debt (mrq) 4.89M USD
Total Debt/Equity (mrq) 0.8 USD
Current Ratio (mrq) 14.327
Book Value Per Share (mrq) 11.531

Cash Flow Statement

Operating Cash Flow (ttm) -118864000 USD
Levered Free Cash Flow (ttm) -42870248 USD

Profile of Prothena

Country United States
State N/A
City Dublin
Address 77 Sir John Rogerson’s Quay
ZIP 2
Phone 353 1 236 2500
Website https://www.prothena.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 127

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Q&A For Prothena Stock

What is a current PRTA stock price?

Prothena PRTA stock price today per share is 25.09 USD.

How to purchase Prothena stock?

You can buy PRTA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Prothena?

The stock symbol or ticker of Prothena is PRTA.

Which industry does the Prothena company belong to?

The Prothena industry is Biotechnology.

How many shares does Prothena have in circulation?

The max supply of Prothena shares is 53.72M.

What is Prothena Price to Earnings Ratio (PE Ratio)?

Prothena PE Ratio is now.

What was Prothena earnings per share over the trailing 12 months (TTM)?

Prothena EPS is -2.76 USD over the trailing 12 months.

Which sector does the Prothena company belong to?

The Prothena sector is Healthcare.

Prothena PRTA included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD